Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Share Finance Facility

15 Sep 2005 08:00

ReGen Therapeutics PLC15 September 2005 ReGen Therapeutics Plc Date 15 September 2005 Committed Share Finance Facility ReGen Therapeutics Plc ("ReGen" or the "Company") announces that on 14thSeptember 2005 it entered into an agreement with the Headstart Group of funds ("Headstart") under which Headstart will make available to the Company acommitted share finance facility of up to Β£2,000,000 (the "Headstart Facility"). Pursuant to the terms of the Headstart Facility, Headstart has agreed, whencalled upon by the Company, to subscribe for, or purchase, new ordinary sharesin the capital of the Company ("Ordinary Shares") to the value of up to, inaggregate, Β£2,000,000. The Headstart Facility is available at any time up to 3years from the date a Committed Share Finance Facility Agreement is entered intoby the Company and Headstart and can be drawn down by the Company in incrementsof up to Β£50,000. The subscription price for an Ordinary Share shall be equalto 95% of the lowest closing bid price of an Ordinary Share in the fifteentrading days following the date on which the Company notifies Headstart that itwishes to make a draw down under the Headstart Facility. In consideration for Headstart making available the Headstart Facility, theCompany has agreed to pay Headstart a one-off underwriting commission of Β£60,000payable by the issue of Ordinary Shares (on the basis of an agreed value perOrdinary Share of 1.35p, being the closing bid price on Wednesday 7th September2005). Β£30,000 of the underwriting commission was payable upon entering into theHeadstart Facility and the remaining Β£30,000 is payable on the first anniversarythereafter. Accordingly, application has been made for 2,222,222 OrdinaryShares to be admitted to trading on the AIM market. It is expected thatadmission to listing will become effective and that dealings in these shareswill commence on Tuesday 20th September 2005. In addition, the Company hasagreed, subject to shareholder approval, to issue warrants granting Headstartthe right to subscribe for up to 4,000,000 Ordinary Shares at a subscriptionprice of 1.65p per share, being a price equal to 110% of the closing bid priceof the Company's shares on 13th September 2005. Such warrants will beexercisable at any time on or before 14th September 2008. As the issue of theWarrants is subject to shareholder approval, ReGen will shortly send toshareholders a circular containing a notice convening an extraordinary generalmeeting of the Company (the "Circular") for 10.00 a.m. on 10 October 2005 (the "EGM") containing resolutions to, inter alia, approve the issue of the Warrants. Copies of the Circular will be available, for collection only, free of charge tothe public, from the Company, Suite 406, Langham House, 29-30 Margaret Street,London W1W 8SA during normal office hours on any day (Saturdays, Sundaysexcepted) from 19 September 2005 until 14 October 2005. - For further information, please contact:Andrew MarshallMarshall Robinson RoeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.